Arrowhead Pharmaceuticals...
18.04
-0.87 (-4.60%)
At close: Jan 14, 2025, 3:59 PM
18.38
1.88%
After-hours Jan 14, 2025, 04:09 PM EST
undefined%
Bid 18.01
Market Cap 2.24B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -5
PE Ratio (ttm) -3.61
Forward PE n/a
Analyst Buy
Ask 18.3
Volume 983,673
Avg. Volume (20D) 1,515,385
Open 19.04
Previous Close 18.91
Day's Range 18.02 - 19.07
52-Week Range 17.05 - 36.72
Beta undefined

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 1993
Employees 525
Stock Exchange NASDAQ
Ticker Symbol ARWR

Analyst Forecast

According to 10 analyst ratings, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 132.82% from the latest price.

Buy 60.00%
Hold 40.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Arrowhead Pharmaceuticals Inc. is scheduled to release its earnings on Feb 4, 2025, during market hours.
Analysts project revenue of $14.09M, reflecting a 296.79% YoY growth and earnings per share of -1.1, making a -11.29% decrease YoY.
1 month ago · Source
+24.23%
Arrowhead Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription
1 month ago · Source
+12.03%
Arrowhead Pharmaceuticals shares are trading higher after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.